Published in
Taylor and Francis Group, Journal of Medical Economics (JME), 4(22), p. 306-318, 2019
DOI: 10.1080/13696998.2018.1563404
Links
Tools
Rivaroxaban for non-valvular atrial fibrillation and venous thromboembolism in the Netherlands: a real-world data based cost-effectiveness analysis
Journal article published in 2019 by
Lisa Aniek de Jong 
,
Judith J. Gout-Zwart,
Marina van den Bosch,
Mike Koops,
Maarten J. Postma
,
Judith J. Gout-Zwart,
Marina van den Bosch,
Mike Koops,
Maarten J. Postma
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 